<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924268</article-id><article-id pub-id-type="pmc">6954586</article-id><article-id pub-id-type="publisher-id">4890</article-id><article-id pub-id-type="doi">10.1186/s13104-020-4890-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group></article-categories><title-group><article-title>Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of <italic>Pseudomonas aeruginosa</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kamali</surname><given-names>Esmat</given-names></name><address><email>esmatkm.2222@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jamali</surname><given-names>Ailar</given-names></name><address><email>jamali@goums.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2386-8366</contrib-id><name><surname>Ardebili</surname><given-names>Abdollah</given-names></name><address><email>ardebili_abdollah57@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ezadi</surname><given-names>Freshteh</given-names></name><address><email>fereshtehezadi92@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohebbi</surname><given-names>Alireza</given-names></name><address><email>alirezaa2s@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution>Laboratory Sciences Research Center, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution>Department of Microbiology, Faculty of Medicine, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution>Stem Cell Research Center, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><elocation-id>27</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1"><italic>Pseudomonas aeruginosa</italic> is known as a leading cause of nosocomial infections worldwide. Antimicrobial resistance and biofilm production, as two main virulence factors of <italic>P. aeruginosa</italic>, are responsible for the persistence of prolonged infections. In this study, antimicrobial susceptibility pattern and phenotypic and genotypic characteristics of biofilm of <italic>P. aeruginosa</italic> were investigated.</p></sec><sec><title>Results</title><p id="Par2">A total of 80 clinical <italic>P. aeruginosa</italic> isolates were obtained. Isolates showed resistance to all antibiotics with a rate from 12.5% (n&#x02009;=&#x02009;10) against amikacin and piperacillin/tazobactam to 23.75% (n&#x02009;=&#x02009;19) to levofloxacin. Multidrug-resistant <italic>P. aeruginosa</italic> accounted for 20% (n&#x02009;=&#x02009;16). 83.75% (n&#x02009;=&#x02009;67) of isolates showed biofilm phenotype. All three biofilm-related genes were found simultaneously in 87.5% (n&#x02009;=&#x02009;70) of <italic>P. aeruginosa</italic> and 13.5% (n&#x02009;=&#x02009;10) of the isolates had none of the genes tested. From the results of the present study, combination therapy including an anti-pseudomonal beta-lactam (piperacillin/tazobactam or ceftazidime) and an aminoglycoside or carbapenems (imipenem, meropenem) with fluoroquinolones in conjunction with an aminoglycoside can be used against <italic>Pseudomonas</italic> infections. However, reasonable antimicrobial use and high standards of infection prevention and control are essential to prevent further development of antimicrobial resistance. Combination strategies based on the proper anti-pseudomonal antibiotics along with anti-biofilm agents can also be selected to eradicate biofilm-associated infections.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antimicrobial resistance</kwd><kwd>Biofilm formation</kwd><kwd>Biofilm genes</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008091</institution-id><institution>Golestan University of Medical Sciences</institution></institution-wrap></funding-source><award-id>110212</award-id><principal-award-recipient><name><surname>Ardebili</surname><given-names>Abdollah</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par14"><italic>Pseudomonas aeruginosa</italic>, as one of the most common hospital pathogens, is involved in a wide of severe opportunistic infections, particularly in immunocompromised patients [<xref ref-type="bibr" rid="CR1">1</xref>]. As a global problem, the increasing rate of multidrug-resistance (MDR) strains has resulted in the medical therapy against <italic>P. aeruginosa</italic> be complicated [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, the ability of <italic>P. aeruginosa</italic> to produce biofilm is thought to be a main factor involved in chronic infections. Biofilms are complex of microbial cells embedded in an extracellular matrix composed of proteins, extracellular DNA, and exopolysaccharides, providing a protective life-style for bacteria and are extremely challenging and costly to treat by antimicrobial compounds [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par15">The biofilm components of <italic>P. aeruginosa</italic> are composed of at least three distinct exopolysaccharides, including alginate, Psl and Pel [<xref ref-type="bibr" rid="CR6">6</xref>]. Alginate is mainly produced by <italic>P. aeruginosa</italic> clinical isolates originated from the lungs of cystic fibrosis (CF) patients [<xref ref-type="bibr" rid="CR7">7</xref>]. It is a linear polymer consisting of &#x003b2;-<sc>d</sc>-mannuronic acid and &#x003b1;-<sc>l</sc>-guluronic acid and has an important role in structural stability and protection of biofilm [<xref ref-type="bibr" rid="CR8">8</xref>]. Alginate synthesis in <italic>P. aeruginosa</italic> is controlled by the <italic>algACD</italic> operon. AlgD encoded by <italic>algD</italic> is a GDP-mannose dehydrogenase that catalyzes the production of GDP-mannuronic acid from GDP-mannose [<xref ref-type="bibr" rid="CR9">9</xref>]. The <italic>algD</italic> gene mediates the control of alginate biosynthesis and transcription of the Alg proteins, and also is responsible for the final production of precursor GDP-mannuronic acid, the foundation molecule for polymerization and alginate synthesis [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par16"><italic>P. aeruginosa</italic> isolates obtained from environments often produce two different exopolysaccharides. Psl (polysaccharide synthesis locus) is a neutral polysaccharide composed of a repeating pentasaccharide, consisting of <sc>d</sc>-mannose, <sc>d</sc>-glucose, and <sc>l</sc>-rhamnose. Psl has been shown that provides cell&#x02013;cell and cell&#x02013;surface interactions during biofilm formation, thereby playing an important in the initiation of biofilm formation and protection of biofilm structure [<xref ref-type="bibr" rid="CR10">10</xref>]. The <italic>psl</italic> operon consisting of 15 co-transcribed genes (<italic>pslA</italic> to <italic>pslO</italic>) is required for Psl synthesis. PslD protein, encoded by <italic>pslD</italic> gene, is localized in the periplasm/outer membrane and is required for biofilm formation, probably by the export of a biofilm-relevant exopolysaccharide [<xref ref-type="bibr" rid="CR11">11</xref>]. The formation of a layer of polymer/cells at the air&#x02013;liquid interface of a <italic>P. aeruginosa</italic> standing culture is termed pellicle formation that is controlled by the <italic>pel</italic> (pellicle) operon [<xref ref-type="bibr" rid="CR12">12</xref>]. Pel is a cellulose-sensitive exopolysaccharide composed of 1&#x02192;4 linked partially acetylated galactosamine and glucosamine sugars [<xref ref-type="bibr" rid="CR13">13</xref>]. The <italic>pel</italic> operon is composed of seven genes (<italic>pelA</italic> to <italic>pelG</italic>) [<xref ref-type="bibr" rid="CR14">14</xref>]. PelF has been suggested to be a soluble glycosyltransferase using UDP-glucose as a donor substrate toward the Pel exopolysaccharide biosynthesis [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par17">Given the potential of biofilm in increasing antimicrobial resistance and, as a result, the persistence of infections caused by <italic>P. aeruginosa</italic>, identification of the isolates possessing such factor will help us to better understand the pathogenesis of the organism. This study aimed to evaluate the antimicrobial susceptibility pattern as well as the phenotypic and genotypic characteristics of biofilm in <italic>P. aeruginosa</italic> isolates.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Methods</title><p id="Par18">Bacterial isolates were collected during September 2017 to August 2018 from clinical specimens of patients in three university affiliated hospitals in Gorgran, Iran. Laboratory identification of <italic>P. aeruginosa</italic> isolates were performed by standard microbiological and biochemical methods, including pigment production in agar, oxidase and catalase tests, reactions in triple sugar iron (TSI)&#x000a0;agar, SIM (sulfide, indole, motility), and oxidative-fermentative (OF) media (Merck, Darmstadt, Germany), and finally, growth at 42&#x000a0;&#x000b0;C [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par19">Susceptibility of isolates to different antibiotics was determined by disk diffusion agar method on cation-adjusted Mueller&#x02013;Hinton agar (Merck, Darmstadt, Germany) according to the Clinical and Laboratory Standards Institute (CLSI) recommendations [<xref ref-type="bibr" rid="CR15">15</xref>]. Antibiotic disks (MAST Diagnostics, Merseyside, UK) tested were ceftazidime (CAZ, 30&#x000a0;&#x003bc;g), piperacillin/tazobactam (PTZ, 100&#x000a0;&#x003bc;g/10&#x000a0;&#x003bc;g), ciprofloxacin (CIP, 5&#x000a0;&#x003bc;g), levofloxacin (LEV, 5&#x000a0;&#x003bc;g), gentamicin (GM, 10&#x000a0;&#x003bc;g), amikacin (AK, 30&#x000a0;&#x003bc;g), tobramycin (TOB, 10&#x000a0;&#x003bc;g), imipenem (IMI, 10&#x000a0;&#x003bc;g), and meropenem (MEM, 10&#x000a0;&#x003bc;g). <italic>Escherichia coli</italic> ATCC 25922 was used as a control for susceptibility testing. Multidrug-resistant <italic>P. aeruginosa</italic> (MDR-PA) was defined as isolate resistant to more than one antimicrobial agent in three or more antimicrobial categories [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par20">Quantitative assessment of biofilm formation was performed by the colorimetric microtiter plate assay as described previously by Stepanovi&#x00107; et al. [<xref ref-type="bibr" rid="CR17">17</xref>] with some modifications. An overnight culture of <italic>P. aeruginosa</italic> was adjusted to the turbidity of a 1 McFarland standard. Suspensions were diluted 1:100 in 200 &#x003bc;L tryptic soy broth (TSB) containing 1% glucose (Merck, Darmstadt, Germany), and were then transferred into the sterile flat-bottomed 96-well polystyrene microplates (JET Biofil, Guangzhou, China). Wells were gently washed three times with sterile phosphate buffered saline (PBS, pH 7.3) after 24&#x000a0;h of incubation at 37&#x000a0;&#x000b0;C. Adherent biofilms were fixed by 99% methanol for 15&#x000a0;min, the solutions were removed, and the plate was air-dried. Biofilms were stained by 200 &#x003bc;L of crystal violet 0.1% (Sigma Chemical Co., St Louis, MO, USA) for 5&#x000a0;min at room temperature, and then rinsed by water and allowed to dry. Biofilm in each well was destained by treatment with 200 &#x003bc;L of 95% ethanol for 30&#x000a0;min. The optical density (OD) was measured at 570&#x000a0;nm using a microtiter plate reader (BioTek, Bad Friedrichshall, Germany). All experiments were performed in triplicate and repeated three times. In addition, a cut-off value (ODc) was established. It is defined as three standard deviations (SD) above the mean OD of the negative control: Odc&#x02009;=&#x02009;average OD of negative control&#x02009;+&#x02009;(3&#x02009;&#x000d7;&#x02009;SD of negative control). The isolates were classified into the four following categories based upon the OD: non-biofilm producer (OD&#x02009;&#x0003c;&#x02009;ODc); weak-biofilm producer (ODc&#x02009;&#x0003c;&#x02009;OD&#x02009;&#x0003c;&#x02009;2&#x02009;&#x000d7;&#x02009;ODc); moderate-biofilm producer (2&#x02009;&#x000d7;&#x02009;ODc&#x02009;&#x0003c;&#x02009;OD&#x02009;&#x0003c;&#x02009;4&#x02009;&#x000d7;&#x02009;ODc); strong-biofilm producer (4&#x02009;&#x000d7;&#x02009;ODc&#x02009;&#x0003c;&#x02009;OD).</p><p id="Par21">All <italic>P. aeruginosa</italic> isolates were evaluated for three biofilm-encoding genes, <italic>algD</italic>, <italic>pslD</italic>, and <italic>pelF</italic> by polymerase chain reaction (PCR) method, using specific primers [<xref ref-type="bibr" rid="CR8">8</xref>] synthesized by Metabion company (Metabion international AG, Germany). DNA extraction was performed from bacterial colonies by boiling method. All three genes were amplified under the following thermal conditions: initial denaturation at 95&#x000a0;&#x000b0;C for 5&#x000a0;min, followed by 30 cycles of denaturation at 94&#x000a0;&#x000b0;C for 30&#x000a0;s, annealing at 60&#x000a0;&#x000b0;C for 40&#x000a0;s, extension at 72&#x000a0;&#x000b0;C for 40&#x000a0;s, and a final elongation step at 72&#x000a0;&#x000b0;C for 5&#x000a0;min. PCR products were analyzed with UV light after running at 100&#x000a0;V for 1&#x000a0;h on a 1% agarose gel stained with DNA safe stain (SinaClon, Tehran, Iran).</p><p id="Par22">Chi squared test was performed on the relationship between categorical variables, including biofilm characteristics and antimicrobial resistance using SPSS software, 18.0 (SPSS Inc., Chicago, IL, USA). A <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered as statistically significant.</p></sec></sec><sec id="Sec4"><title>Results</title><p id="Par23">A total of 80 distinct <italic>P. aeruginosa</italic> isolates were obtained from patients, of which 44 (55%) were from males and 36 (45%) were from females. Analysis of <italic>P. aeruginosa</italic> distribution in clinical specimens indicated that the most isolates (n&#x02009;=&#x02009;29, 36.25%) were originated from endotracheal secretions, followed by urine (n&#x02009;=&#x02009;26, 32.5%), blood (n&#x02009;=&#x02009;11, 13.75%), wound (n&#x02009;=&#x02009;8, 10%), CSF (n&#x02009;=&#x02009;4, 5%), and ear (n&#x02009;=&#x02009;2, 2.5%).</p><p id="Par24">Based on the&#x000a0;CLSI interpretive criteria [<xref ref-type="bibr" rid="CR15">15</xref>], resistance rate among <italic>P. aeruginosa</italic> isolates to antibiotics tested was as follow (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>): IMI 22.5% (n&#x02009;=&#x02009;18), MEM 15% (n&#x02009;=&#x02009;12), GM 18.75% (n&#x02009;=&#x02009;15), TN 16.25% (n&#x02009;=&#x02009;13), AK 12.5% (n&#x02009;=&#x02009;10), CIP 20% (n&#x02009;=&#x02009;16), LEV 23.75 (n&#x02009;=&#x02009;19), CAZ 17.5% (n&#x02009;=&#x02009;14), and PTZ 12.5% (n&#x02009;=&#x02009;10). The prevalence of MDR-PA and non-MDR-PA was 20% (n&#x02009;=&#x02009;16) and 80% (n&#x02009;=&#x02009;64), respectively.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Antibiotic susceptibility patterns of <italic>P. aeruginosa</italic> clinical isolates. <italic>IMI</italic> imipenem, <italic>MEM</italic> meropenem, <italic>GM</italic> gentamicin, <italic>TOB</italic> tobramycin, <italic>AK</italic> amikacin, <italic>CIP</italic> ciprofloxacin, <italic>LEV</italic> levofloxacin, <italic>CAZ</italic> ceftazidime, <italic>PTZ</italic> piperacillin/tazobactam</p></caption><graphic xlink:href="13104_2020_4890_Fig1_HTML" id="MO1"/></fig></p><p id="Par25">Biofilm phenotypes accounted for 83.75% (n&#x02009;=&#x02009;67), being distributed in the following categories: 16.25% (n&#x02009;=&#x02009;13) produced strong biofilm; 33.75% (n&#x02009;=&#x02009;27) produced moderate biofilm; 33.75% (n&#x02009;=&#x02009;27) produced weak biofilm, whilst 16.25% of isolates (n&#x02009;=&#x02009;13) were identified as non-biofilm producer (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A high occurrence of biofilm-encoding genes was found&#x000a0;(Fig. <xref rid="Fig2" ref-type="fig">2</xref>): 87.5% (n&#x02009;=&#x02009;70) of the isolates presented all three <italic>algD</italic>, <italic>pslD</italic>, and <italic>pelF</italic> genes, simultaneously (identified as <italic>algD&#x02009;</italic><sup>+</sup>/<italic>pslD&#x02009;</italic><sup>+</sup>/<italic>pelF&#x02009;</italic><sup>+</sup> genotypic pattern), while 12.5% (n&#x02009;=&#x02009;10) had none and considered as <italic>algD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pslD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pelF&#x02009;</italic><sup>&#x02212;</sup> pattern. In addition, isolates were divided to four groups based on both phenotypic and genotypic characteristics of biofilm: biofilm positive/gene positive (n&#x02009;=&#x02009;59, 73.75%); biofilm negative/gene positive (n&#x02009;=&#x02009;11, 13.75%); biofilm positive/gene negative (n&#x02009;=&#x02009;8, 10%); biofilm negative/gene negative (n&#x02009;=&#x02009;2, 2.5%). MDR phenotype accounted for 17.91% (n&#x02009;=&#x02009;12) of 67 biofilm producers and 20% (n&#x02009;=&#x02009;14) of 70 genotypically positive isolates.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Relationship between biofilm characteristic and antibiotic susceptibility pattern among <italic>P. aeruginosa</italic> clinical isolates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Phenotypic pattern of biofilm, no. (%)</th><th align="left" colspan="3">Genotypic pattern of biofilm, no. (%)</th></tr><tr><th align="left"><italic>AlgD&#x02009;</italic><sup>+</sup>/<italic>pslD&#x02009;</italic><sup>+</sup><italic>/pelF&#x02009;</italic><sup>+</sup></th><th align="left"><italic>AlgD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pslD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pelF&#x02009;</italic><sup>&#x02212;</sup></th><th align="left">p-value</th></tr></thead><tbody><tr><td align="left">Strong, 13 (16.25)</td><td char="(" align="char">10 (76.92)</td><td char="(" align="char">3 (23.07)</td><td char="." align="char">0.001</td></tr><tr><td align="left">Moderate, 27 (33.75)</td><td char="(" align="char">25 (92.59)</td><td char="(" align="char">2 (7.41)</td><td char="." align="char">0.0001</td></tr><tr><td align="left">Weak 27 (33.75)</td><td char="(" align="char">24 (88.89)</td><td char="(" align="char">3 (11.11)</td><td char="." align="char">0.0001</td></tr><tr><td align="left">Non-biofilm, 13 (16.25)</td><td char="(" align="char">11 (84.61)</td><td char="(" align="char">2 (15.38)</td><td char="." align="char">0.0001</td></tr><tr><td align="left">Total, 80 (100)</td><td char="(" align="char">70 (87.5)</td><td char="(" align="char">10 (12.5)</td><td char="." align="char">0.0001</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>PCR amplification of biofilm-encoding genes in one selected clinical isolate of <italic>P. aeruginosa</italic> as representative. <bold>a</bold> Lane 1&#x02013;3: PCR products of the <italic>pelF</italic>, <italic>algD</italic>, and <italic>pslD</italic> genes, respectively. M: 50&#x000a0;bp DNA ladder. Lane 4: PCR mixture without DNA template as control negative. Lane 5&#x02013;7: PCR products of the corresponding genes in <italic>P. aeruginosa</italic> PAO1 reference strain as control positive. <bold>b</bold> A 50&#x000a0;bp DNA ladder containing seventeen discrete fragments ranging from 50 to 1500&#x000a0;bp with double intensity reference bands at 200&#x000a0;bp, 500&#x000a0;bp, and 1200&#x000a0;bp</p></caption><graphic xlink:href="13104_2020_4890_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec5"><title>Discussion</title><p id="Par26">Development of resistance by <italic>P. aeruginosa</italic> to many antimicrobial agents is a great challenge in controlling its infections [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Comprehensive surveillance of antimicrobial resistance in European countries for 2017 demonstrated a range of combined resistance (resistance to three or more antimicrobial groups, including piperacillin&#x02009;&#x000b1;&#x02009;tazobactam, ceftazidime, fluoroquinolones, aminoglycosides and carbapenems) from 0% (Iceland) to 59.1% (Romania) [<xref ref-type="bibr" rid="CR20">20</xref>]. The prevalence of MDR <italic>P. aeruginosa</italic> in Iran has been estimated at 58%, with a variation in geographical areas: the highest and lowest rates were observed in Tehran (100%) and Zahedan (16%), respectively [<xref ref-type="bibr" rid="CR21">21</xref>]. In a recent study, Bavasheh et al. [<xref ref-type="bibr" rid="CR22">22</xref>] found that 27.8% of clinical <italic>P. aeruginosa</italic> isolates were MDR. Similarly, the rate of isolates with resistance to at least three antimicrobial groups in our study was 20% that was lower than that reported from other studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Although the rate of multi-resistance in the present study was relatively low, this may be an alarming situation that reflects a threat limiting treatment options in therapeutic centers studied.</p><p id="Par27">Similar to the results of other studies [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], a significant number of included isolates (83.75%) formed biofilm. The present study revealed a high prevalence of <italic>algD</italic>, <italic>pslD</italic>, and <italic>pelF</italic> genes, being presented simultaneously in a considerable proportion (87.5%) of <italic>P. aeruginosa</italic> isolates, a finding that are similar to those found by Banar et al. [<xref ref-type="bibr" rid="CR8">8</xref>]. Other genes associated with biofilm formation, such as <italic>pslA</italic> and <italic>pelA</italic> were detected by Ghadaksaz et al. [<xref ref-type="bibr" rid="CR27">27</xref>] with a frequency of 83.7% and 45.2%, respectively, and Pournajaf et al. [<xref ref-type="bibr" rid="CR25">25</xref>] with a frequency of 89.5% and 57.3%, respectively among <italic>P. aeruginosa</italic> clinical isolates. However, little data is available about the prevalence rate of <italic>pslD</italic> and <italic>pelF</italic> genes in different regions of the world.</p><p id="Par28">In agreement with other studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], our results revealed a significant correlation between the biofilm forming capacity and the presence of relevant genes (p-value&#x02009;&#x0003c;&#x02009;0.0001). About 88.06% of 67 biofilm producer isolates showed <italic>algD&#x02009;</italic><sup>+</sup>/<italic>pslD&#x02009;</italic><sup>+</sup>/<italic>pelF&#x02009;</italic><sup>+</sup> genotypic pattern, while 11.94% were <italic>algD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pslD&#x02009;</italic><sup>&#x02212;</sup>/<italic>pelF&#x02009;</italic><sup>&#x02212;</sup>. On the other hand, 84.61% of 13 non-biofilm producers carried biofilm genes. The capacity of biofilm production despite the absence of biofilm genes studied indicates other genetic determinants of biofilm participate in matrix formation in <italic>P. aeruginosa</italic> [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. By contrast, the presence of genes without biofilm production may be due to chromosomal mutations in different regulatory systems, affecting the production of functional biofilm-associated proteins. Hou et al. [<xref ref-type="bibr" rid="CR30">30</xref>] reported that no <italic>P. aeruginosa</italic> isolates were phenotypically positive for biofilm formation in Congo red agar and microtiter plate assays, whereas 31.03% of isolates contained the <italic>pslA</italic> gene. Conformational changes in quorum sensing proteins due to mutations in <italic>lasI/lasR</italic> and <italic>rhlI/rhlR</italic> systems were suggested in previous studies [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>] as the reason why these isolates are unable to produce biofilm.</p><p id="Par29">According to the results of this study, <italic>P. aeruginosa</italic> that produced biofilm and also those carried biofilm-associated genes were mainly considered as non-MDR. This may cause a misunderstanding in the first place that biofilm production is not related to antibiotic resistance. It is noteworthy that all isolates in our study were subjected to antimicrobial susceptibility testing as planktonic cells and not in biofilm form. Thus, multiple mechanisms of biofilm and its architectural features, including glycocalyx matrix, outer membrane structure, heterogeneity in metabolism and growth rate, persister cells formation, genetic adaptation, stress responses as well as quorum sensing conferring MDR phenotype were not involved [<xref ref-type="bibr" rid="CR34">34</xref>]. Regardless, Lima et al. [<xref ref-type="bibr" rid="CR31">31</xref>] in Brazil found 48.4% of biofilm producer <italic>P. aeruginosa</italic> isolates were MDR and 51.6% were non-MDR. In another study, Abidi et al. [<xref ref-type="bibr" rid="CR35">35</xref>] reported that biofilm production was significantly higher in MDR isolates.</p><p id="Par30">In conclusion, combination therapy including an anti-pseudomonal beta-lactam (piperacillin/tazobactam or ceftazidime) and an aminoglycoside or carbapenems (imipenem, meropenem) with fluoroquinolones in conjunction with an aminoglycoside can be used against <italic>Pseudomonas</italic> infections. Although the rate of resistance to multiple antibiotics among the <italic>P. aeruginosa</italic> isolates was relatively low in the present study, prudent antimicrobial use and high standards of infection prevention and control are essential to prevent further development of resistant strains. In addition, combination strategies based on the proper anti-pseudomonal antibiotics with anti-biofilm agents can be used to enhance the treatment of biofilm-associated infections.</p></sec><sec id="Sec6"><title>Limitations</title><p id="Par31">This study may be limited by the lack of clinical information of the patients (treatment, prescription drugs, mortality rate, length of a hospital stay) from whom bacteria were isolated. Furthermore, this study indicates that determination of expression levels of biofilm-associated genes by quantitative real-time PCR may help to evaluate the role of each corresponding gene in biofilm production.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CF</term><def><p id="Par3">cystic fibrosis</p></def></def-item><def-item><term>CLSI</term><def><p id="Par4">Clinical and Laboratory Standards Institute</p></def></def-item><def-item><term>MDR-PA</term><def><p id="Par5">multidrug-resistant <italic>P. aeruginosa</italic></p></def></def-item><def-item><term>OD</term><def><p id="Par6">optical density</p></def></def-item><def-item><term>OF</term><def><p id="Par7">oxidative-fermentative</p></def></def-item><def-item><term>Pel</term><def><p id="Par8">pellicle</p></def></def-item><def-item><term>PCR</term><def><p id="Par9">polymerase chain reaction</p></def></def-item><def-item><term>Psl</term><def><p id="Par10">polysaccharide synthesis locus</p></def></def-item><def-item><term>SIM</term><def><p id="Par11">sulfide, indole, motility</p></def></def-item><def-item><term>TSB</term><def><p id="Par12">tryptic soy broth</p></def></def-item><def-item><term>TSI</term><def><p id="Par13">triple sugar iron</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to appreciate the staffs of hospitals and all colleagues at the Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran, for their cooperation in the present study.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AA conceived, designed, and supervised the study and revised the manuscript; EK and FE performed the experiments and drafted the manuscript; AA, and AJ analyzed and interpreted the data; AM contributed to statistical analysis. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The present study was financially supported by Golestan University of Medical Sciences, Gorgan, Iran, with Grant Number 110212.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data associated with this study are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par32">All stages of this study was approved by the Ethics Committee of Golestan University of Medical Sciences with the ethical code number IR.GUMS.REC.1397.142. All included patients were informed orally of the purpose and experimental procedures of the study. However, they did not directly participate in this project. All experiments were performed on bacteria isolated from clinical samples of admitted patients to hospitals.</p></notes><notes><title>Consent for publication</title><p id="Par33">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pachori</surname><given-names>P</given-names></name><name><surname>Gothalwal</surname><given-names>R</given-names></name><name><surname>Gandhi</surname><given-names>P</given-names></name></person-group><article-title>Emergence of antibiotic resistance <italic>Pseudomonas aeruginosa</italic> in intensive care unit; a critical review</article-title><source>Genes Dis</source><year>2019</year><volume>6</volume><issue>2</issue><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">31194018</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogonchi</surname><given-names>AA</given-names></name><name><surname>Ghaemi</surname><given-names>EA</given-names></name><name><surname>Ardebili</surname><given-names>A</given-names></name><name><surname>Yazdansetad</surname><given-names>S</given-names></name><name><surname>Pournajaf</surname><given-names>A</given-names></name></person-group><article-title>Metallo-&#x003b2;-lactamase-mediated resistance among clinical carbapenem-resistant <italic>Pseudomonas aeruginosa</italic> isolates in northern Iran: a potential threat to clinical therapeutics</article-title><source>Tzu Chi Med J</source><year>2018</year><volume>30</volume><issue>2</issue><fpage>90</fpage><lpage>96</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bijari</surname><given-names>A</given-names></name><name><surname>Azimi</surname><given-names>L</given-names></name><name><surname>Fallah</surname><given-names>F</given-names></name><name><surname>Ardebili</surname><given-names>A</given-names></name><name><surname>Rastegar Lari</surname><given-names>E</given-names></name><name><surname>Rastegar</surname><given-names>Lari A</given-names></name></person-group><article-title>Involvement of the multidrug efflux pumps in betalactams resistant <italic>Pseudomonas aerugionsa</italic> clinical isolates collected from burn patients in Iran</article-title><source>Infect Disord Drug Targets</source><year>2016</year><volume>16</volume><issue>3</issue><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">27572250</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>MR</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>MP</given-names></name><name><surname>Rodrigues</surname><given-names>AA</given-names></name><name><surname>Gontijo Filho</surname><given-names>PP</given-names></name></person-group><article-title>Antimicrobial use, incidence, etiology and resistance patterns in bacteria causing ventilator-associated pneumonia in a clinical-surgical intensive care unit</article-title><source>Rev Soc Bras Med Trop</source><year>2013</year><volume>46</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">23563823</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Hill</surname><given-names>PJ</given-names></name><name><surname>Snarr</surname><given-names>BD</given-names></name><name><surname>Alnabelseya</surname><given-names>N</given-names></name><name><surname>Pestrak</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent <italic>Pseudomonas aeruginosa</italic> biofilms</article-title><source>Sci Adv</source><year>2016</year><volume>2</volume><issue>5</issue><fpage>e1501632</fpage><pub-id pub-id-type="pmid">27386527</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>MJ</given-names></name><name><surname>Nivens</surname><given-names>DE</given-names></name><name><surname>Weadge</surname><given-names>JT</given-names></name><name><surname>Howell</surname><given-names>PL</given-names></name></person-group><article-title>Biosynthesis of the <italic>Pseudomonas aeruginosa</italic> extracellular polysaccharides, alginate, Pel, and Psl</article-title><source>Front Microbiol</source><year>2011</year><volume>2</volume><fpage>167</fpage><pub-id pub-id-type="pmid">21991261</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govan</surname><given-names>JR</given-names></name><name><surname>Deretic</surname><given-names>V</given-names></name></person-group><article-title>Microbial pathogenesis in cystic fibrosis: mucoid <italic>Pseudomonas aeruginosa</italic> and <italic>Burkholderia cepacia</italic></article-title><source>Microbiol Mol Biol Rev</source><year>1996</year><volume>60</volume><issue>3</issue><fpage>539</fpage><lpage>574</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banar</surname><given-names>M</given-names></name><name><surname>Emaneini</surname><given-names>M</given-names></name><name><surname>Satarzadeh</surname><given-names>M</given-names></name><name><surname>Abdellahi</surname><given-names>N</given-names></name><name><surname>Beigverdi</surname><given-names>R</given-names></name><name><surname>van Leeuwen</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Evaluation of mannosidase and trypsin enzymes effects on biofilm production of <italic>Pseudomonas aeruginosa</italic> isolated from burn wound infections</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>10</issue><fpage>e0164622</fpage><pub-id pub-id-type="pmid">27736961</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laverty</surname><given-names>G</given-names></name><name><surname>Gorman</surname><given-names>SP</given-names></name><name><surname>Gilmore</surname><given-names>BF</given-names></name></person-group><article-title>Biomolecular mechanisms of <italic>Pseudomonas aeruginosa</italic> and <italic>Escherichia coli</italic> biofilm formation</article-title><source>Pathogens</source><year>2014</year><volume>3</volume><issue>3</issue><fpage>596</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">25438014</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Conover</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Parsek</surname><given-names>MR</given-names></name><name><surname>Bayles</surname><given-names>K</given-names></name><name><surname>Wozniak</surname><given-names>DJ</given-names></name></person-group><article-title>Assembly and development of the <italic>Pseudomonas aeruginosa</italic> biofilm matrix</article-title><source>PLoS Pathog</source><year>2009</year><volume>5</volume><issue>3</issue><fpage>e1000354</fpage><pub-id pub-id-type="pmid">19325879</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campisano</surname><given-names>A</given-names></name><name><surname>Schroeder</surname><given-names>C</given-names></name><name><surname>Schemionek</surname><given-names>M</given-names></name><name><surname>Overhage</surname><given-names>J</given-names></name><name><surname>Rehm</surname><given-names>BH</given-names></name></person-group><article-title>PslD is a secreted protein required for biofilm formation by <italic>Pseudomonas aeruginosa</italic></article-title><source>Appl Environ Microbiol</source><year>2006</year><volume>72</volume><issue>4</issue><fpage>3066</fpage><lpage>3068</lpage><pub-id pub-id-type="pmid">16598021</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafoor</surname><given-names>A</given-names></name><name><surname>Jordens</surname><given-names>Z</given-names></name><name><surname>Rehm</surname><given-names>BH</given-names></name></person-group><article-title>Role of PelF in Pel polysaccharide biosynthesis in <italic>Pseudomonas aeruginosa</italic></article-title><source>Appl Environ Microbiol</source><year>2013</year><volume>79</volume><issue>9</issue><fpage>2968</fpage><lpage>2978</lpage><pub-id pub-id-type="pmid">23435893</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>LK</given-names></name><name><surname>Storek</surname><given-names>KM</given-names></name><name><surname>Ledvina</surname><given-names>HE</given-names></name><name><surname>Coulon</surname><given-names>C</given-names></name><name><surname>Marmont</surname><given-names>LS</given-names></name><name><surname>Sadovskaya</surname><given-names>I</given-names></name><etal/></person-group><article-title>Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the <italic>Pseudomonas aeruginosa</italic> biofilm matrix</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><issue>36</issue><fpage>11353</fpage><lpage>11358</lpage><pub-id pub-id-type="pmid">26311845</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>L</given-names></name><name><surname>Kolter</surname><given-names>R</given-names></name></person-group><article-title>Genes involved in matrix formation in <italic>Pseudomonas aeruginosa</italic> PA14 biofilms</article-title><source>Mol Microbiol</source><year>2004</year><volume>51</volume><issue>3</issue><fpage>675</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">14731271</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 28th ed. M100. Wayne: Clinical and Laboratory Standards Institute (CLSI); 2018. p. 38.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magiorakos</surname><given-names>AP</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>R</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name><name><surname>Falagas</surname><given-names>M</given-names></name><name><surname>Giske</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clin Microbiol Infect</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">21793988</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanovi&#x00107;</surname><given-names>S</given-names></name><name><surname>Vukovi&#x00107;</surname><given-names>D</given-names></name><name><surname>Hola</surname><given-names>V</given-names></name><name><surname>Bonaventura</surname><given-names>GD</given-names></name><name><surname>Djuki&#x00107;</surname><given-names>S</given-names></name><name><surname>&#x00106;irkovi&#x00107;</surname><given-names>I</given-names></name><etal/></person-group><article-title>Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci</article-title><source>APMIS</source><year>2007</year><volume>115</volume><issue>8</issue><fpage>891</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">17696944</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>J</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>KH</given-names></name></person-group><article-title>Prevalence of multidrug-resistant, extensively drug-resistant, and pandrug-resistant <italic>Pseudomonas aeruginosa</italic> from a tertiary level intensive care unit</article-title><source>J Glob Infect Dis</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">27942195</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000fc;mmler</surname><given-names>B</given-names></name></person-group><article-title>Emerging therapies against infections with <italic>Pseudomonas aeruginosa</italic></article-title><source>F1000Res</source><year>2019</year><pub-id pub-id-type="pmid">31448090</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe 2017. <ext-link ext-link-type="uri" xlink:href="https://ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017">https://ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017</ext-link>. Accessed 15 Nov 2018.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaez</surname><given-names>H</given-names></name><name><surname>Salehi-Abargouei</surname><given-names>A</given-names></name><name><surname>Ghalehnoo</surname><given-names>ZR</given-names></name><name><surname>Khademi</surname><given-names>F</given-names></name></person-group><article-title>Multidrug resistant <italic>Pseudomonas aeruginosa</italic> in Iran: a systematic review and metaanalysis</article-title><source>J Glob Infect Dis</source><year>2018</year><volume>10</volume><issue>4</issue><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">30581263</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavasheh</surname><given-names>N</given-names></name><name><surname>Karmostaji</surname><given-names>A</given-names></name></person-group><article-title>Antibiotic resistance pattern and evaluation of blaOXA-10, blaPER-1, blaVEB, blaSHV genes in clinical isolates of <italic>Pseudomonas aeruginosa</italic> isolated from hospital in south of Iran in 2014&#x02013;2015</article-title><source>Infect Epidemiol Microbiol</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikokar</surname><given-names>I</given-names></name><name><surname>Tishayar</surname><given-names>A</given-names></name><name><surname>Flakiyan</surname><given-names>Z</given-names></name><name><surname>Alijani</surname><given-names>K</given-names></name><name><surname>Rehana-Banisaeed</surname><given-names>S</given-names></name><name><surname>Hossinpour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibiotic resistance and frequency of class 1 integrons among <italic>Pseudomonas aeruginosa</italic>, isolated from burn patients in Guilan, Iran</article-title><source>Iran J Microbiol</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23466812</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faghri</surname><given-names>J</given-names></name><name><surname>Nouri</surname><given-names>S</given-names></name><name><surname>Jalalifar</surname><given-names>S</given-names></name><name><surname>Zalipoor</surname><given-names>M</given-names></name><name><surname>Halaji</surname><given-names>M</given-names></name></person-group><article-title>Investigation of antimicrobial susceptibility, class I and II integrons among <italic>Pseudomonas aeruginosa</italic> isolates from hospitalized patients in Isfahan, Iran</article-title><source>BMC Res Notes</source><year>2018</year><volume>11</volume><issue>1</issue><fpage>806</fpage><pub-id pub-id-type="pmid">30419962</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pournajaf</surname><given-names>A</given-names></name><name><surname>Razavi</surname><given-names>S</given-names></name><name><surname>Irajian</surname><given-names>G</given-names></name><name><surname>Ardebili</surname><given-names>A</given-names></name><name><surname>Erfani</surname><given-names>Y</given-names></name><name><surname>Solgi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis <italic>Pseudomonas aeruginosa</italic> isolates</article-title><source>Infez Med</source><year>2018</year><volume>26</volume><issue>3</issue><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">30246765</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasiljevi&#x00107;</surname><given-names>Z</given-names></name><name><surname>Jov&#x0010d;i&#x00107;</surname><given-names>B</given-names></name><name><surname>&#x00106;irkovi&#x00107;</surname><given-names>I</given-names></name><name><surname>&#x00110;uki&#x00107;</surname><given-names>S</given-names></name></person-group><article-title>An examination of potential differences in biofilm production among different genotypes of <italic>Pseudomonas aeruginosa</italic></article-title><source>Arch Biol Sci</source><year>2014</year><volume>66</volume><issue>1</issue><fpage>117</fpage><lpage>121</lpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadaksaz</surname><given-names>A</given-names></name><name><surname>Fooladi</surname><given-names>AAI</given-names></name><name><surname>Hosseini</surname><given-names>HM</given-names></name><name><surname>Amin</surname><given-names>M</given-names></name></person-group><article-title>The prevalence of some <italic>Pseudomonas</italic> virulence genes related to biofilm formation and alginate production among clinical isolates</article-title><source>J App Biomed</source><year>2015</year><volume>13</volume><issue>1</issue><fpage>61</fpage><lpage>68</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;sken</surname><given-names>M</given-names></name><name><surname>Di Fiore</surname><given-names>S</given-names></name><name><surname>D&#x000f6;tsch</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>H&#x000e4;ussler</surname><given-names>S</given-names></name></person-group><article-title>Genetic determinants of <italic>Pseudomonas aeruginosa</italic> biofilm establishment</article-title><source>Microbiol</source><year>2010</year><volume>156</volume><issue>2</issue><fpage>431</fpage><lpage>441</lpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moradali</surname><given-names>MF</given-names></name><name><surname>Ghods</surname><given-names>S</given-names></name><name><surname>Rehm</surname><given-names>BH</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> lifestyle: a paradigm for adaptation, survival, and persistence</article-title><source>Front Cell Infect Microbiol</source><year>2017</year><volume>7</volume><fpage>39</fpage><pub-id pub-id-type="pmid">28261568</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Biofilm-forming capacity of <italic>Staphylococcus epidermidis</italic>, <italic>Staphylococcus aureus</italic>, and <italic>Pseudomonas aeruginosa</italic> from ocular infections</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><issue>9</issue><fpage>5624</fpage><lpage>5631</lpage><pub-id pub-id-type="pmid">22736609</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>JLdC</given-names></name><name><surname>Alves</surname><given-names>LR</given-names></name><name><surname>Jacom&#x000e9;</surname><given-names>PRLA</given-names></name><name><surname>Neto</surname><given-names>B</given-names></name><name><surname>Pac&#x000ed;fico</surname><given-names>J</given-names></name><name><surname>Maciel</surname><given-names>MAV</given-names></name><etal/></person-group><article-title>Biofilm production by clinical isolates of <italic>Pseudomonas aeruginosa</italic> and structural changes in LasR protein of isolates non biofilm-producing</article-title><source>Braz J Infect Dis</source><year>2018</year><volume>22</volume><issue>2</issue><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">29601791</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjarnsholt</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>P&#x000d8;</given-names></name><name><surname>Jakobsen</surname><given-names>TH</given-names></name><name><surname>Phipps</surname><given-names>R</given-names></name><name><surname>Nielsen</surname><given-names>AK</given-names></name><name><surname>Rybtke</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Quorum sensing and virulence of <italic>Pseudomonas aeruginosa</italic> during lung infection of cystic fibrosis patients</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>4</issue><fpage>e10115</fpage><pub-id pub-id-type="pmid">20404933</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senturk</surname><given-names>S</given-names></name><name><surname>Ulusoy</surname><given-names>S</given-names></name><name><surname>Bosgelmez-Tinaz</surname><given-names>G</given-names></name><name><surname>Yagci</surname><given-names>A</given-names></name></person-group><article-title>Quorum sensing and virulence of <italic>Pseudomonas aeruginosa</italic> during urinary tract infections</article-title><source>J Infect Dev Ctries</source><year>2012</year><volume>6</volume><issue>6</issue><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">22706193</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Chowdhury</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><article-title>Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents</article-title><source>Open Microbiol. J</source><year>2017</year><volume>11</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">28553416</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abidi</surname><given-names>SH</given-names></name><name><surname>Sherwani</surname><given-names>SK</given-names></name><name><surname>Siddiqui</surname><given-names>TR</given-names></name><name><surname>Bashir</surname><given-names>A</given-names></name><name><surname>Kazmi</surname><given-names>SU</given-names></name></person-group><article-title>Drug resistance profile and biofilm forming potential of <italic>Pseudomonas aeruginosa</italic> isolated from contact lenses in Karachi-Pakistan</article-title><source>BMC Ophthalmol</source><year>2013</year><volume>13</volume><fpage>57</fpage><pub-id pub-id-type="pmid">24134792</pub-id></element-citation></ref></ref-list></back></article>